A machine learning–based tool accurately predicted risk for recurrent inflammatory activity after DMT discontinuation in MS, highlighting its potential to guide personalized treatment decisions.

Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI ...

A new study in the Journal of Psychopharmacology questions whether psychedelics reliably enhance creative thinking, finding ...

Work on medical uses of mind-altering substances was sidelined for decades by the political backlash against drugs, a misstep ...

Biogen's Spinraza is not the first drug to face a CMC-related rejection recently, as SMA competitor drug, apitegromab, also ...

DMT, or dimethyltryptamine is a natural psychoactive molecule found in many plants and mammals. According to an article published in Science Advances ...

A stem cell transplant lowers the risk of PIRA in people with aggressive RRMS more effectively than standard drug therapies, ...

Keith Tan, [email protected], Zhuo ling Heng, [email protected], Kyla Koh, [email protected] | Iron ...

Alaska activists have officially launched a signature drive to place an initiative on the 2026 ballot to legalize certain ...

Research into whether drugs like ayahuasca can mitigate the effects of traumatic brain injury is in its infancy. Pro athletes like the Buffalo Bills’ Jordan Poyer are forging ahead anyway.

Massachusetts lawmakers have approved a bill to establish a pilot program for the regulated therapeutic use of psychedelics.